logo
  Join        Login             Stock Quote

ISIS Pharmaceuticals (ISIS) Tumbles After CHMP Adopts Negative Opinion On Kynamro

 December 14, 2012 08:13 AM
 


(By Balachander) ISIS Pharmaceuticals Inc. (NASDAQ: ISIS) shares tumbled in Friday premarket trading after an European Committee recommended the refusal of the marketing authorisation for its lead product Kynamro intended to treat high blood cholesterol levels, citing saftety concerns.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on Thursday adopted a negative opinion for Kynamro for the treatment of patients with an inherited disease causing high blood cholesterol levels, called familial hypercholesterolaemia.

The CHMP was of the opinion that the benefits of Kynamro did not outweigh its risks and recommended that it be refused marketing authorisation.

[Related -Futures Down Ahead Of Service Sector Data; Compugen Ltd. (CGEN) Soars]

The Committee noted that a high proportion of patients stopped taking the medicine within two years, mainly due to side effects such as flu-like symptoms, injections site reactions and liver toxicity. The Committee was also concerned that a greater proportion of patients taking Kynamro experienced serious cardiovascular events (problems with the heart and blood vessels) than patients taking placebo.

"This prevented the CHMP from concluding that Kynamro's intended cardiovascular benefit, in terms of reducing cholesterol levels, outweighed its cardiovascular risk," CHMP said.

Genzyme, a Sanofi company (NYSE: SNY) and ISIS' partner, plans to request a re-examination of the CHMP Opinion.

[Related -Futures Down On China Worries; Vanguard Health Systems Inc. (VHSSurge]

In October 2012, KYNAMRO received a positive vote by an U.S. Food and Drug Administration (FDA) advisory panel that Genzyme had provided sufficient efficacy and safety data to support the marketing of KYNAMRO to treat HoFH.

ISIS shares dropped 8.95 percent in Friday pre-market trade.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageReversals After a Gap on the Open Could Mean Anything

Yesterday stock indexes gapped up on the open but then reversed course to close sharply lower. This type of read on...

article imageJobless Claims Fall To 15-Year Low

After reading today’s weekly update on jobless claims the Fed’s comment yesterday that “economic activity read on...

article imageGreece, EMU and Democracy

One more post on Greece, possibly not the last read on...

article imageA Tangled Tale Of Rate Hikes & Inflation Expectations

The Federal Reserve continues to signal that it will start raising interest rates later this year, read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.